Hepatitis

Sofosbuvir, velpatasvir, and voxilaprevir successful in patients with hepatitis C virus infection, with and without HIV co-infection, including those with prior noncompletion of treatment or poor adherence to direct-acting antiviral drug regimens.

The epidemiology of hepatitis A has shifted from point-source outbreaks to outbreaks caused by person-to-person transmission.

People who inject drugs may still able to achieve a cure of hepatitis C virus infection with treatment with direct-acting antivirals.

Interferon lambda 4 represents a vulnerability that benefits hepatitis C virus to the detriment of humans.

Treatment regimens consisting of daclatasvir plus sofosbuvir plus ribavirin and velpatasvir/sofosbuvir plus ribavirin show similar cure rates in patients with hepatitis C virus genotype 2 and 3.

Targeting interleukin (IL)-17A and IL-22 proteins may help delay the development of hepatic fibrosis.

Stigma may cause undiagnosed individuals with HIV to go unidentified and fail to get quality care and treatment.

All-oral direct-acting antivirals had a significant effect on the clinical and economic outcomes of patients with hepatitis C virus in the 4 years following the approval of these treatments.

Hepatitis B virus infectivity can remain stable for up to 9 months and demonstrate high resilience to antiseptics.

Top news of the day from across the health care landscape.

Hepatitis C virus found to increase mortality in individuals coinfected with HIV, however, treatment with direct-acting antivirals may reduce harm.

Top news of the day from across the health care landscape.

Australia on track to achieve World Health Organization targets for eliminating hepatitis C virus over the next 10 to 15 years.

An association between hepatitis C virus infection and incident diabetes found among patients who underwent kidney transplantation.

One-time, universal screening of hepatitis C virus (HCV) in the general population is cost-effective and could reduce rates of drug-related HCV cases.

Recent preclinical and population evidence shows cannabis modulates inflammatory and fibrotic processes in the liver, which is promising for treating the symptoms of hepatitis C virus.

Study investigates whether direct-acting antiviral drugs for hepatitis C virus increase the risk of developing hepatocellular carcinoma.

The national Veterans Health Administration Corporate Data Warehouse could be key in revealing accurate data on the use of direct-acting antivirals in the treatment of chronic hepatitis C virus.

Glecaprevir/pibrentasvir found to be effective in clinical trials treating patients with hepatitis C virus also being treated for opioid substitution therapy.

Top news of the day from across the health care landscape.

A new review of clinical trial data show the combination therapy elbasvir/grazoprevir (EBR/GR) has high rates of efficacy for patients with genotypes 1a, 1b, and 4 chronic hepatitis C (HCV) infection.

In light of new evidence supporting the efficacy of hepatitis C virus (HCV) treatments in individuals who use or inject drugs, researchers are urging the removal of restrictions that prevent recent drug users from accessing lifesaving HCV therapies.

Based on evidence from a systematic review, researchers are calling for increased access to lifesaving hepatitis C treatments for injection drug users.

Top news of the week from Specialty Pharmacy Times.

Officials with Gilead Sciences, Inc. plan to launch authorized generic versions of Epclusa and Harvoni.

Study establishes real-world efficacy, tolerability, and safety profile of sofosbuvir-based regimens in patients with chronic hepatitis C who have compensated liver cirrhosis.

Top news of the day from across the health care landscape.

Study shows that it’s cost-effective to use the livers of HCV-positive patients even with the cost of direct-acting antiviral drugs to cure the virus.

Researchers have identified a potential point of intervention that could prevent the progression of liver damage to cancer.